Items where Author is "Ladenburger, S."
 | Up a level |
Article
Sterneck, M. and Kaiser, G. M. and Heyne, N. and Richter, N. and Rauchfuss, F. and Pascher, A. and Schemmer, P. and Fischer, L. and Klein, C. G. and Nadalin, S. and Lehner, F. and Settmacher, U. and Neuhaus, P. and Gotthardt, D. and Loss, M. and Ladenburger, S. and Paulus, E. M. and Mertens, M. and Schlitt, H. J. (2014) Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation. AMERICAN JOURNAL OF TRANSPLANTATION, 14 (3). pp. 701-710. ISSN 1600-6135, 1600-6143
Fischer, L. and Lehner, F. and Neuhaus, P. and Schmidt, J. and Thomas, B. and Hack, M. A. and Ladenburger, S. and Schlitt, H.J. (2012) The PROTECT Study: Preservation of Renal Function in Liver Transplant Recipients with Certican-Based vs CNI-Based Therapy. AMERICAN JOURNAL OF TRANSPLANTATION, 12 (s3). p. 125. ISSN 1600-6135
Fischer, L. and Klempnauer, J. and Beckebaum, S. and Metselaar, H. J. and Neuhaus, P. and Schemmer, P. and Settmacher, U. and Heyne, N. and Clavien, P-A and Muehlbacher, F. and Morard, I. and Wolters, H. and Vogel, W. and Becker, T. and Sterneck, M. and Lehner, F. and Klein, C. and Kazemier, G. and Pascher, A. and Schmidt, J. and Rauchfuss, F. and Schnitzbauer, A. and Nadalin, S. and Hack, M. and Ladenburger, S. and Schlitt, H. J. (2012) A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation - PROTECT. AMERICAN JOURNAL OF TRANSPLANTATION, 12 (7). pp. 1855-1865. ISSN 1600-6135
Schlitt, H. J. and Lehner, F. and Neuhaus, P. and Schmidt, J. and Becker, T. and Hack, M. A. and Ladenburger, S. and Fischer, L. (2011) THE PROTECT STUDY: PRESERVATION OF RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH CERTICAN-BASED VS CNI-BASED THERAPY. TRANSPLANT INTERNATIONAL, 24 (Suppl3). p. 22. ISSN 0934-0874
Puehler, Thomas and Goepel, L. and Von Tschirschnitz, M. and Struckmeyer, U. and Ernst, M. and Ladenburger, S. and Schmid, C. and Cremer, J. and Hirt, S. W. (2007) C2 therapeutic drug monitoring of cyclosporine is a safe and feasible method in de novo heart transplant patients. TRANSPLANTATION PROCEEDINGS, 39 (10). pp. 3329-3333. ISSN 0041-1345, 1873-2623
